10-K · February 24, 2026
Myriad describes a strategy focused on the Cancer Care Continuum, Prenatal Health and Mental Health, leveraging its legacy hereditary-cancer leadership, new partnerships (PATHOMIQ, SOPHiA GENETICS) and next‑generation…
Earnings analysis · 10-Q
MYGN earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2.3% year-over-year but missed consensus estimates. The company also faced a net loss of $34.1 million, translating to a diluted EPS of $-0.36, exacerbated…
Read full summary
Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2.3% year-over-year but missed consensus estimates. The company also faced a net loss of $34.1 million, translating to a diluted EPS of $-0.36, exacerbated by goodwill impairment charges. Overall, management reaffirmed its guidance for full-year revenue of $860 - $880 million, highlighting growth in key segments despite ongoing operating losses.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.36
- Gross margin
- 68.7%
What stood out
-
Annual Revenue Growth
Q1 2026 revenue increased 2.3% from $195.9 million in Q1 2025 to $200.4 million.
-
Mental Health Segment Growth
Mental Health segment revenue rose by $7.3 million, a 23.5% increase from $31.0 million in the prior year.
-
Gross Margin Improvement
Gross margin improved slightly to 68.7% in Q1 2026 from 68.5% in Q1 2025.
-
Lower Operating Expense Ratio
General and administrative expenses decreased, leading to a reduction from 33.9% to 31.0% of total revenue.
-
Maintained Full-Year Guidance
Management reiterated full-year revenue guidance of $860-$880 million, unchanged from prior expectations.
-
Stable Cancer Care Revenue
Cancer Care Continuum revenue grew $4.6 million year-over-year despite an 8% decrease in revenue per test.
What to watch
-
Substantial Net Loss
Q1 2026 net loss increased to $34.1 million compared to $31.1 million in Q1 2025.
-
Goodwill Impairment Charges
Recorded $5.4 million in goodwill and intangible asset impairment charges.
-
Heavy Interest Expense Growth
Other expense net rose by $3.0 million to $(3.4) million due to increased interest expenses from debt.
Management's outlook
Management confirmed full year 2026 revenue guidance.
Earlier filings 4
10-Q · November 4, 2025
Myriad reported Q3 2025 revenue of $205.7M (down $7.6M vs. $213.3M in Q3 2024) and a GAAP net loss of $27.4M (EPS $(0.29)). Results show sequential operating and EPS recovery from the Q2 2025 impairment quarter, but…
10-Q · August 6, 2025
Myriad reported Q2 revenue of $213.1M (vs $211.5M a year ago) but recorded $316.7M of goodwill and long‑lived asset impairment charges driving an operating loss of $329.2M and a net loss of $330.5M (EPS $(3.57)).…
10-Q · May 7, 2025
Myriad reported Q1 2025 revenue of $195.9 million, down from $202.2 million in Q1 2024, with gross profit of $134.2 million (~68.5% gross margin) and an operating loss of $29.0 million (−14.8% margin). The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.